Does the media refer more to BLTE or PBH?

In the previous week, Belite Bio had 2 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat Belite Bio's score of 0.31 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prestige Consumer Healthcare 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LNTH or PBH?

In the previous week, Lantheus and Lantheus both had 3 articles in the media. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat Lantheus' score of 0.38 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prestige Consumer Healthcare 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LQDA or PBH?

In the previous week, Liquidia had 39 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 42 mentions for Liquidia and 3 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat Liquidia's score of -0.03 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 4 Very Positive mention(s) 8 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Prestige Consumer Healthcare 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prestige Consumer Healthcare (PBH) Competitors

$47.87 +0.30 (+0.62%)

Closing price 03:59 PM Eastern

Extended Trading

$47.87 +0.00 (+0.01%)

As of 07:30 PM Eastern

Compare

PBH vs. BLTE, LNTH, AMRX, LQDA, and DFTX

Should you buy Prestige Consumer Healthcare stock or one of its competitors? Prestige Consumer Healthcare's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Liquidia (LQDA), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Prestige Consumer Healthcare compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Belite Bio has a beta of -1.23, indicating that its stock price is 223% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Belite Bio's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Belite Bio presently has a consensus price target of $218.73, suggesting a potential upside of 40.14%. Prestige Consumer Healthcare has a consensus price target of $67.67, suggesting a potential upside of 42.23%. Given Prestige Consumer Healthcare's higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Prestige Consumer Healthcare	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Belite Bio had 2 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat Belite Bio's score of 0.31 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prestige Consumer Healthcare	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prestige Consumer Healthcare has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Prestige Consumer Healthcare	$1.09B	2.07	$190.30M	$3.57	13.33

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

In the previous week, Lantheus and Lantheus both had 3 articles in the media. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat Lantheus' score of 0.38 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prestige Consumer Healthcare	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Lantheus has higher revenue and earnings than Prestige Consumer Healthcare. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.20
Prestige Consumer Healthcare	$1.09B	2.07	$190.30M	$3.57	13.33

99.1% of Lantheus shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus currently has a consensus target price of $108.11, suggesting a potential upside of 7.92%. Prestige Consumer Healthcare has a consensus target price of $67.67, suggesting a potential upside of 42.23%. Given Prestige Consumer Healthcare's stronger consensus rating and higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Prestige Consumer Healthcare	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Lantheus has a net margin of 17.69% compared to Prestige Consumer Healthcare's net margin of 15.57%. Lantheus' return on equity of 28.10% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Summary

Lantheus beats Prestige Consumer Healthcare on 10 of the 16 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Amneal Pharmaceuticals?

Prestige Consumer Healthcare (NYSE:PBH) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Prestige Consumer Healthcare has higher earnings, but lower revenue than Amneal Pharmaceuticals. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	2.07	$190.30M	$3.57	13.33
Amneal Pharmaceuticals	$3.02B	2.08	$72.06M	$0.49	40.10

Prestige Consumer Healthcare has a net margin of 15.57% compared to Amneal Pharmaceuticals' net margin of 5.05%. Prestige Consumer Healthcare's return on equity of 11.39% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Prestige Consumer Healthcare has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

In the previous week, Prestige Consumer Healthcare had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 3 mentions for Prestige Consumer Healthcare and 2 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.93 beat Prestige Consumer Healthcare's score of 0.92 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prestige Consumer Healthcare	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Prestige Consumer Healthcare presently has a consensus target price of $67.67, suggesting a potential upside of 42.23%. Amneal Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 6.87%. Given Prestige Consumer Healthcare's higher possible upside, research analysts plainly believe Prestige Consumer Healthcare is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Amneal Pharmaceuticals beats Prestige Consumer Healthcare on 9 of the 17 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Liquidia has a net margin of 30.74% compared to Prestige Consumer Healthcare's net margin of 15.57%. Liquidia's return on equity of 149.65% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

64.5% of Liquidia shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Liquidia has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Prestige Consumer Healthcare has higher revenue and earnings than Liquidia. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	15.08	-$68.92M	$1.37	19.47
Prestige Consumer Healthcare	$1.09B	2.07	$190.30M	$3.57	13.33

Liquidia currently has a consensus price target of $83.69, suggesting a potential upside of 213.69%. Prestige Consumer Healthcare has a consensus price target of $67.67, suggesting a potential upside of 42.23%. Given Liquidia's higher possible upside, equities research analysts plainly believe Liquidia is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25
Prestige Consumer Healthcare	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Liquidia had 39 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 42 mentions for Liquidia and 3 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat Liquidia's score of -0.03 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	4 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Neutral
Prestige Consumer Healthcare	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Liquidia beats Prestige Consumer Healthcare on 10 of the 16 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Prestige Consumer Healthcare has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Prestige Consumer Healthcare	$1.09B	2.07	$190.30M	$3.57	13.33

In the previous week, Definium Therapeutics had 1 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 4 mentions for Definium Therapeutics and 3 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.92 beat Definium Therapeutics' score of 0.50 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prestige Consumer Healthcare	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Definium Therapeutics' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Definium Therapeutics presently has a consensus target price of $64.88, suggesting a potential upside of 84.88%. Prestige Consumer Healthcare has a consensus target price of $67.67, suggesting a potential upside of 42.23%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Definium Therapeutics is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prestige Consumer Healthcare	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Definium Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Summary

Prestige Consumer Healthcare beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Prestige Consumer Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBH vs. The Competition

Export

Metric	Prestige Consumer Healthcare	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.25B	$12.25B	$7.14B	$22.87B
Dividend Yield	N/A	2.65%	2.53%	3.71%
P/E Ratio	13.41	802.39	275.15	28.01
Price / Sales	2.08	747.53	566.78	19.88
Price / Cash	9.13	86.04	77.41	38.14
Price / Book	1.20	10.66	10.80	4.70
Net Income	$190.30M	$2.83B	$3.50B	$1.07B
7 Day Performance	7.14%	-1.62%	-2.02%	0.63%
1 Month Performance	-3.87%	-7.65%	-7.53%	-4.93%
1 Year Performance	-24.40%	-6.26%	3.32%	5.31%

Prestige Consumer Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBH Prestige Consumer Healthcare	3.6751 of 5 stars	$47.87 +0.6%	$67.67 +41.4%	-24.3%	$2.25B	$1.09B	13.41	890
BLTE Belite Bio	3.3257 of 5 stars	$165.66 -0.2%	$218.73 +32.0%	+101.7%	$6.66B	N/A	N/A	41
LNTH Lantheus	3.2772 of 5 stars	$99.65 -0.1%	$108.11 +8.5%	+93.2%	$6.50B	$1.54B	24.07	1,193
AMRX Amneal Pharmaceuticals	3.0726 of 5 stars	$20.25 -1.2%	$21.00 +3.7%	+89.7%	$6.47B	$3.02B	41.37	8,500	Analyst Downgrade
LQDA Liquidia	4.0307 of 5 stars	$69.30 -5.9%	$98.08 +41.5%	+11.1%	$6.25B	$158.32M	50.96	216	Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PBH) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prestige Consumer Healthcare (PBH) Competitors

PBH vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Prestige Consumer Healthcare compare to Belite Bio?

Summary

How does Prestige Consumer Healthcare compare to Lantheus?

Summary

How does Prestige Consumer Healthcare compare to Amneal Pharmaceuticals?

Summary

How does Prestige Consumer Healthcare compare to Liquidia?

Summary

How does Prestige Consumer Healthcare compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH vs. The Competition

Prestige Consumer Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prestige Consumer Healthcare (PBH) Competitors

PBH vs. BLTE, LNTH, AMRX, LQDA, and DFTX

How does Prestige Consumer Healthcare compare to Belite Bio?

Which has more volatility and risk, BLTE or PBH?

Is BLTE or PBH more profitable?

Do analysts rate BLTE or PBH?

Does the media refer more to BLTE or PBH?

Which has higher valuation and earnings, BLTE or PBH?

Do institutionals & insiders have more ownership in BLTE or PBH?

Summary

How does Prestige Consumer Healthcare compare to Lantheus?

Does the media refer more to LNTH or PBH?

Which has more volatility & risk, LNTH or PBH?

Which has preferable earnings & valuation, LNTH or PBH?

Do insiders & institutionals have more ownership in LNTH or PBH?

Do analysts rate LNTH or PBH?

Is LNTH or PBH more profitable?

Summary

How does Prestige Consumer Healthcare compare to Amneal Pharmaceuticals?

Which has preferable valuation and earnings, PBH or AMRX?

Is PBH or AMRX more profitable?

Which has more volatility and risk, PBH or AMRX?

Does the media favor PBH or AMRX?

Do institutionals & insiders hold more shares of PBH or AMRX?

Do analysts rate PBH or AMRX?

Summary

How does Prestige Consumer Healthcare compare to Liquidia?

Is LQDA or PBH more profitable?

Do insiders & institutionals hold more shares of LQDA or PBH?

Which has more volatility and risk, LQDA or PBH?

Which has higher valuation and earnings, LQDA or PBH?

Do analysts recommend LQDA or PBH?

Does the media refer more to LQDA or PBH?

Summary

How does Prestige Consumer Healthcare compare to Definium Therapeutics?

Which has stronger valuation & earnings, DFTX or PBH?

Does the media refer more to DFTX or PBH?

Do institutionals and insiders hold more shares of DFTX or PBH?

Is DFTX or PBH more profitable?

Do analysts rate DFTX or PBH?

Which has more risk & volatility, DFTX or PBH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH vs. The Competition

Prestige Consumer Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools